No abstract

Introduction:Diagnosis of breast cancer is associated with the presence of psychological disorders including depression. There is a lack of study examining the prevalence of depression among newly diagnosed breast cancer patients in Kazakhstan. Objective: This study aims to assess the prevalence and associated sociodemographic and clinical factors of depression symptoms in women newly diagnosed with breast cancer. Methods: 162 newly diagnosed breast cancer patients at the oncology center in Almaty were recruited for this study. Data were collected using a structured questionnaire on sociodemographic and clinical information and the Beck Depression Inventory-II scale. Results:The mean age of the patients was 54.41 years (SD=8.1). 95% of participants had unilateral breast cancer, and 79% of participants had stage I or stage II breast cancer. 73% of patients said that they do not have reliable social support. 46% of patients had symptoms of moderate depression, and 31% of patients had symptoms of severe depression. According to the multivariate analysis, factors associated with depression symptoms were: social status, household income level, reliability of social support, and stage of breast cancer. Conclusion: The prevalence of depression symptoms is very high among newly diagnosed breast cancer patients. Unemployed or retired patients, with a lower household income, and no reliable social support diagnosed with an advanced stage of breast cancer are especially at high risk for developing depression.

Introduction:Diagnosis of breast cancer is associated with high psychological distress. There is a lack of studies examining the prevalence of anxiety among newly diagnosed breast cancer patients in Kazakhstan. Objective: This study aims to assess the mean prevalence and associated sociodemographic and clinical factors of anxiety symptoms in women newly diagnosed with breast cancer. It also aims to determine independent predictors of anxiety risk. Methods: An analysis of 162 newly diagnosed breast cancer patients at the oncology institute in Almaty was performed. Data were collected using a structured questionnaire on social, demographic, and clinical information, as well as the Beck Anxiety Inventory. In addition, multiple regression analysis was used to model the relationship between anxiety risk and independent predictors. Results: The average age of the patients was 54.41 years (SD=8.1; min.-max: 32-75). The majority of the patients were married (52%), employed or self-employed (51%), had children (91%), had a bachelor's or a graduate degree (50%), lived in an urban area (54%), did not drink (41%), did not smoke (67%), did not engage in physical activity (54%), and had social support (91%). A total of 48% of patients had symptoms of moderate anxiety, and 33% had symptoms of severe anxiety. Based on the multivariate analysis, factors associated with a lower risk of anxiety symptoms included higher household income (OR -2.21 (95 CI: -1.35, -3.07)) and having reliable social support (OR -2.93 (95% CI: -2.25, -3.61)). Conclusion: The prevalence of anxiety symptoms is very high among newly diagnosed breast cancer patients. Anxiety is more likely to develop in patients from low-income households and those without reliable social support.

No abstract

subset of QOL measures collected were evaluated to determine the impact of aBC/mBC or its treatment on productivity, energy, and physical activity in patients treated with palbociclib.Material and methods: Patients indicated weekly how aBC/mBC or its treatment interfered with family/social life and limited productivity, physical activities and energy on a 5-point scales ("Not at all", "A little bit", "Moderately", "Quite a bit", "A great deal") as well as employment status. Daily pain and fatigue severity were measured on an 11-point scale (0-10, 10 being worst possible pain/fatigue) and averaged to create weekly scores. Patient demographic and clinical data including adverse events was recorded in an eCRF. The relationship between weekly productivity limitation ("not at all" or "a little bit" vs. "moderately" to "a great deal") and neutropenia (yes/no), pain (<2 vs ≥2), and fatigue (<2 vs ≥2) was evaluated using generalized linear logistic models.Results: Twenty-five sites contributed 139 patients (median [range] age 60 [34, 82]; white: 83%; ECOG 0-1: 87%). About half of patients (49%) were employed at baseline and employment status was generally stable over time when excluding missing data and early withdrawals. Most patients across the first week of all cycles indicated aBC/mBC or its treatment limited or interfered physical activity, energy or stamina, mood or emotions, productivity, family life, and social life "Not at all" or "A little". These findings were similar regardless of experience with neutropenia. The overall odds ratio (95% CI) for pain and fatigue severity >2 vs. severity ≤2 on productivity limitation from aBC/mBC or its treatment of was 5.8 (3.3, 10.2) and 8.2 (4.8, 14.0) respectively.Conclusions: The majority of patients treated with palbociclib in the MADELINE study indicated aBC/mBC or its treatment limited productivity, energy, and physical activity "Not at all" or "A little". Employment was stable across cycles for patients remaining in the study. While results suggest a low level of pain and fatigue in the study, there was a significant effect on productivity limitation with higher levels of pain and fatigue associated with higher limitations on productivity. Neutropenia was not associated with higher limitations on productivity.

No abstract